Alvotech (ALVO) Q4 2025 earnings review
Guidance Met, But Quality of Earnings is a Major Red Flag
Alvotech hit its FY25 revenue and EBITDA targets, but the underlying composition is alarming. Product revenue decelerated sharply in the second half of the year, plummeting to just $43M in Q4. The quarter was effectively salvaged by a massive $128M injection of lumpy licensing milestones. Furthermore, repeated FDA manufacturing issues at the Reykjavik facility have pushed crucial U.S. BLA approvals to late 2026. While the European rollout offers a bright spot and the company secured $208M in fresh financing to bridge the gap, leaning heavily on one-time milestone payments to mask core commercial struggles is unsustainable.
🐂 Bull Case
AVT05 (Simponi), AVT03 (Prolia/Xgeva), and AVT06 (Eylea) were all approved in the UK, EEA, and Japan. This ex-U.S. commercial traction provides immediate revenue diversification while U.S. approvals are delayed.
FY25 Adjusted EBITDA grew 27% YoY to $137M, and the company posted its first positive annual Operating Cash Flow ($7M). The business is scaling structurally despite quarterly lumpiness.
🐻 Bear Case
Despite a narrative of 'commercial momentum,' product revenue dropped 70% from $146M in 24Q4 to $43M in 25Q4. If product sales don't recover, the business model breaks when licensing milestones run out.
CRLs related to the Reykjavik manufacturing facility mean U.S. approvals for four major BLAs are delayed until late 2026, starving the company of high-margin U.S. product revenue for another year.
⚖️ Verdict: 🔴
Bearish. Management is painting a rosy picture using licensing milestones to hide a severe deceleration in actual product sales. Until the FDA manufacturing issues are resolved and product margins recover, execution risk remains exceptionally high.
Key Themes
Product Margin and Volume Collapse
Decelerating. A specific data point that heavily contradicts management's 'commercial scale' narrative is the collapse in product margins. Product margin fell from 47% in 24Q4 to 41% in 25Q1, and further compressed to a dismal 14% in 25Q4. Management blamed 'timing of shipments and facility improvements,' but this indicates severe negative operating leverage and potential price erosion.
Reykjavik FDA Inspection Failures
Stable pattern of failure. The company received Complete Response Letters (CRLs) following a July FDA inspection. Consequently, U.S. approvals for Simponi, Simponi Aria, Prolia/Xgeva, and Eylea are delayed. Alvotech aims to resubmit in Q2 2026 for late 2026 approvals. This single point of failure at the Iceland facility continues to handicap the company's most lucrative market.
Macro and Pricing Headwinds
Decelerating. The company faces a tough macro and competitive environment. In Europe, the AVT03 (Prolia/Xgeva) launch is facing 'competitive pricing dynamics.' In the U.S., the Stelara biosimilar market is characterized by aggressive, potentially unsustainable price competition. Additionally, the company faces exposure to a 15% tariff on U.S. imports into Iceland, which could further pressure manufacturing costs.
Rapid European Commercial Rollout
Accelerating. With the U.S. market stalled by regulatory delays, Europe is doing the heavy lifting. AVT05 (Simponi) is the first approved biosimilar in the UK, Europe, and Japan, enjoying limited competition. AVT03 (Prolia) is also launching in Germany and select European markets, transitioning Alvotech from a two-product to a five-product commercial company.
Extensive Pipeline & Process Innovation
Accelerating. The company is leaning into its R&D engine, advancing 30 biosimilar candidates. The acquisition of Xbrane's R&D organization accelerates parallel development. Significant technological progress includes expanded perfusion manufacturing capacity and a pipeline featuring AVT16 (Entyvio) and AVT32 (Keytruda), positioning the company for first-to-market advantages in the late 2020s.
Other KPIs
Reversing. Despite reporting a massive $69M in Adjusted EBITDA in Q4, Operating Cash Flow was actually negative $28M. This divergence was driven by poor revenue collection and an aggressive inventory build-up for upcoming launches. Furthermore, FY25 Net Income of $28M looks good on paper, but it was driven entirely by a $198M non-cash finance income gain from derivative revaluations.
Stable. Gross debt sits at $1.44B. The company successfully executed a $108M convertible bond and a $100M senior term loan facility in Q4, boosting cash to $172M. While this provides the necessary runway to survive the FDA delays, the 12.5% interest rate on the new term loan underscores the high cost of capital.
Guidance
Decelerating. The midpoint of $675M implies a 14% YoY growth rate, which is a deceleration from the 21% growth achieved in FY25. Management explicitly noted that the lower end of this range assumes zero revenues from new launches into the U.S. market in 2026, baking in the FDA regulatory risk.
Accelerating. The midpoint of $200M implies 46% YoY growth, a sharp acceleration compared to the 27% growth seen in FY25. Achieving this will require a massive recovery in product gross margins and successful cost absorption from the newly launched European products.
Key Questions
FDA Remediation Confidence
You received a CRL related to the Reykjavik facility in Q3, pushing U.S. approvals out by over a year. Given the history of inspection failures at this specific site, what structural changes guarantee that the Q2 2026 re-submission will finally clear the FDA?
Product Margin Collapse
Product margins compressed dramatically from 47% in 24Q4 to just 14% in 25Q4. How much of this was truly one-time facility and timing impacts, versus structural price erosion and competitive dynamics in the STELARA and Humira markets?
Licensing Revenue Sustainability
Licensing milestones made up 75% of your total revenue in Q4, effectively saving the quarter. Can you provide a specific bridge for FY26 detailing how much of your $650-$700M guidance relies on lumpy milestones versus recurring product sales?
Cash Burn and Working Capital
Despite generating $69M in Adj EBITDA in Q4, Operating Cash Flow was negative $28M due to inventory builds. With US launches delayed, how many more quarters of working capital drag do you expect before the inventory actually converts to cash?